DOI: 10.5061/dryad.m905qfv4n
title: Cost‑effectiveness analysis of anti‑influenza drugs in adult outpatient settings in Japan

description: The loss of productivity due to influenza virus (flu) infections (3 to 5
 million cases globally), which can sometimes amount to as much as five
 working days, is a major socioeconomic issue. This study compares
 baloxavir marboxil’s cost-effectiveness with that of oseltamivir for
 influenza treatment in adult outpatient settings in Japan from the
 healthcare-payer perspective. A decision tree model was constructed with
 probabilities from CAPSTONE 1 for low-risk patients and CAPSTONE 2 for
 high-risk patients. Direct costs included medical costs and drug prices.
 Medical costs were obtained from the Japanese Medical Fee Index (2019
 version). Effectiveness outcomes (quality-adjusted life-year [QALY]) were
 measured using the EQ-5D-5L questionnaire for adult patients who
 previously experienced flu infection. The time horizon was 14 days.
 Deterministic and probabilistic sensitivity analyses were performed to
 examine the robustness of the results. The base case analysis revealed
 oseltamivir dominated baloxavir marboxil for low-risk patients. However,
 the incremental cost-effectiveness ratio (ICER) for high-risk patients
 with body weight &lt; 80 kg was 3,178,163 yen/QALY (US$ 30,905/QALY),
 which was less than the willingness to pay 5,000,000 yen/QALY (US$
 48,621/QALY).  Moreover, the ICER for high-risk patients with
 influenza and body weight ≥ 80 kg was 10,709,187 yen/QALY (US$
 104,139/QALY). The study revealed baloxavir marboxil was more
 cost-effective than oseltamivir for high-risk patients with body weight
 &lt; 80 kg. As the concept of a formulary in hospitals has gradually
 become popular, healthcare providers may find the insights from this study
 helpful in developing a novel formulary for decision-makers to consider.
description: # Cost-effectiveness analysis of anti-influenza drugs in adult outpatient
 settings in Japan ### File list QOL scores.csv QALY.csv ### File
 descriptions Details for: QOL scores The file is the table of raw data
 using EQ-5D-5L questionnaire. Format(s): .csv Dimensions: 50 rows x 8
 columns Variables: * Patient No: anonymous number of each patient. *
 Disease state 1: QOL score of disease state 1 based on the EQ-5D-5L. *
 Disease state 2: QOL score of disease state 2 based on the EQ-5D-5L. *
 Disease state 3: QOL score of disease state 3 based on the EQ-5D-5L. *
 Disease state 4: QOL score of disease state 4 based on the EQ-5D-5L. *
 Disease state 5: QOL score of disease state 5 based on the EQ-5D-5L. *
 Disease state 6: QOL score of disease state 6 based on the EQ-5D-5L. *
 Disease state 7: QOL score of disease state 7 based on the EQ-5D-5L.
 Details for: QALY.csv The file is the table to be converted each QOL score
 using the formula in the paper. Format(s): .csv Dimensions: 50 rows x 8
 columns Variables: * Patient No: anonymous number of each patient. *
 Disease state 1: QALY of disease state 1 based on the QOL score. * Disease
 state 2: QALY of disease state 2 based on the QOL score. * Disease state
 3: QALY of disease state 3 based on the QOL score. * Disease state 4: QALY
 of disease state 4 based on the QOL score. * Disease state 5: QALY of
 disease state 5 based on the QOL score. * Disease state 6: QALY of disease
 state 6 based on the QOL score. * Disease state 7: QALY of disease state 7
 based on the QOL score.